Table 1.
Baseline Characteristics of IBT and Non-IBT Group.
| IBT group (N = 16029) | Non-IBT group (N = 141214) | P-Value | |
|---|---|---|---|
| Gender | <.0001 | ||
| Female | 7784 (48.56%) | 71692 (50.77%) | |
| Male | 8245 (51.44%) | 69522 (49.23%) | |
| Age Group | <.0001 | ||
| 18-30 | 540 (3.37%) | 5493 (3.25%) | |
| 31-40 | 1782 (11.12%) | 14338 (10.15%) | |
| 41-50 | 3452 (21.54%) | 23520 (16.66%) | |
| 51-60 | 5708 (35.61%) | 34864 (24.69%) | |
| 61-70 | 3659 (22.83%) | 30353 (21.49%) | |
| 71-80 | 857 (5.35%) | 23776 (16.84%) | |
| > 80 | 31 (0.19%) | 9770 (6.92%) | |
| Mean (SD) | 53.48 (11.51) | 58.43 (15.02) | <.0001 |
| Median (IQR) | 55 (15) | 59 (22) | <.0001 |
| CCI Score | <.0001 | ||
| 0 | 3201 (19.97%) | 61495 (43.55%) | |
| 1 | 8273 (51.61%) | 46756 (33.11%) | |
| 2 | 3318 (20.70%) | 20146 (14.27%) | |
| 3 | 744 (4.64%) | 6875 (4.87%) | |
| >=4 | 493 (3.08%) | 5942 (4.21%) | |
| Mean (SD) | 1.23 (1.08) | 0.98 (1.24) | <.0001 |
| Median (IQR) | 1 (1) | 1 (1) | <.0001 |
| Follow up time | |||
| Mean (SD) | 4.53 (2.40) | 3.34 (2.31) | <.0001 |
| Median (IQR) | 4.41 (3.39) | 2.79 (3.48) | <.0001 |
CCI, Charlson comorbidity index; IBT, interferon-based therapy.